Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15355504rdf:typepubmed:Citationlld:pubmed
pubmed-article:15355504lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:15355504lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:15355504lifeskim:mentionsumls-concept:C0035648lld:lifeskim
pubmed-article:15355504lifeskim:mentionsumls-concept:C0002895lld:lifeskim
pubmed-article:15355504lifeskim:mentionsumls-concept:C0005821lld:lifeskim
pubmed-article:15355504lifeskim:mentionsumls-concept:C1801960lld:lifeskim
pubmed-article:15355504lifeskim:mentionsumls-concept:C0009566lld:lifeskim
pubmed-article:15355504lifeskim:mentionsumls-concept:C1947917lld:lifeskim
pubmed-article:15355504lifeskim:mentionsumls-concept:C1882417lld:lifeskim
pubmed-article:15355504pubmed:issue2lld:pubmed
pubmed-article:15355504pubmed:dateCreated2004-9-9lld:pubmed
pubmed-article:15355504pubmed:abstractTextPolymorphisms of platelet membrane glycoproteins such as human platelet antigen (HPA)-1b, HPA-2b, the -5T/C Kozak sequence and C807T have been described as risk factors for vascular disease. Vaso-occlusion episodes are a common feature of sickle cell anaemia (SCA), leading to complications such as stroke, acute chest syndrome, avascular head femur necrosis and priapism. Complex interactions are involved in vaso-occlusion, and activated platelets may play an important role. These data raised the question of whether platelet polymorphisms could be implicated in occlusive vascular complications (OVC) of SCA.lld:pubmed
pubmed-article:15355504pubmed:languageenglld:pubmed
pubmed-article:15355504pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15355504pubmed:citationSubsetIMlld:pubmed
pubmed-article:15355504pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15355504pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15355504pubmed:statusMEDLINElld:pubmed
pubmed-article:15355504pubmed:monthAuglld:pubmed
pubmed-article:15355504pubmed:issn0042-9007lld:pubmed
pubmed-article:15355504pubmed:authorpubmed-author:CostaF FFFlld:pubmed
pubmed-article:15355504pubmed:authorpubmed-author:CastroVVlld:pubmed
pubmed-article:15355504pubmed:authorpubmed-author:FigueiredoM...lld:pubmed
pubmed-article:15355504pubmed:authorpubmed-author:AlbertoF LFLlld:pubmed
pubmed-article:15355504pubmed:authorpubmed-author:Annichino-Biz...lld:pubmed
pubmed-article:15355504pubmed:authorpubmed-author:SaadS T OSTlld:pubmed
pubmed-article:15355504pubmed:authorpubmed-author:GualandroS...lld:pubmed
pubmed-article:15355504pubmed:authorpubmed-author:CostaR N PRNlld:pubmed
pubmed-article:15355504pubmed:authorpubmed-author:Lepikson-Neto...lld:pubmed
pubmed-article:15355504pubmed:issnTypePrintlld:pubmed
pubmed-article:15355504pubmed:volume87lld:pubmed
pubmed-article:15355504pubmed:ownerNLMlld:pubmed
pubmed-article:15355504pubmed:authorsCompleteYlld:pubmed
pubmed-article:15355504pubmed:pagination118-23lld:pubmed
pubmed-article:15355504pubmed:dateRevised2006-8-26lld:pubmed
pubmed-article:15355504pubmed:meshHeadingpubmed-meshheading:15355504...lld:pubmed
pubmed-article:15355504pubmed:meshHeadingpubmed-meshheading:15355504...lld:pubmed
pubmed-article:15355504pubmed:meshHeadingpubmed-meshheading:15355504...lld:pubmed
pubmed-article:15355504pubmed:meshHeadingpubmed-meshheading:15355504...lld:pubmed
pubmed-article:15355504pubmed:meshHeadingpubmed-meshheading:15355504...lld:pubmed
pubmed-article:15355504pubmed:meshHeadingpubmed-meshheading:15355504...lld:pubmed
pubmed-article:15355504pubmed:meshHeadingpubmed-meshheading:15355504...lld:pubmed
pubmed-article:15355504pubmed:meshHeadingpubmed-meshheading:15355504...lld:pubmed
pubmed-article:15355504pubmed:meshHeadingpubmed-meshheading:15355504...lld:pubmed
pubmed-article:15355504pubmed:meshHeadingpubmed-meshheading:15355504...lld:pubmed
pubmed-article:15355504pubmed:meshHeadingpubmed-meshheading:15355504...lld:pubmed
pubmed-article:15355504pubmed:meshHeadingpubmed-meshheading:15355504...lld:pubmed
pubmed-article:15355504pubmed:year2004lld:pubmed
pubmed-article:15355504pubmed:articleTitlePolymorphism of the human platelet antigen-5 system is a risk factor for occlusive vascular complications in patients with sickle cell anemia.lld:pubmed
pubmed-article:15355504pubmed:affiliationHematology and Hemotherapy Center, State University of Campinas-UNICAMP, São Paulo, Brazil. vagner@unicamp.brlld:pubmed
pubmed-article:15355504pubmed:publicationTypeJournal Articlelld:pubmed
entrez-gene:3690entrezgene:pubmedpubmed-article:15355504lld:entrezgene
entrez-gene:2811entrezgene:pubmedpubmed-article:15355504lld:entrezgene
entrez-gene:3673entrezgene:pubmedpubmed-article:15355504lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:15355504lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:15355504lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:15355504lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15355504lld:pubmed